ArticleRheumatology (Oxford, England)2025
Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy.International journal of molecular sciences · 2025Review
- Targeted Therapy for Idiopathic Inflammatory Myopathy.Journal of cachexia, sarcopenia and muscle · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate anifrolumab's ability to treat cutaneous and extracutaneous manifestations of dermatomyositis (DM) refractory to conventional systemic therapies.
methodsWe reviewed the records of patients with adult-onset DM managed at the Cutaneous Autoimmune Connective Tissue Disease Clinic in the Department of Dermatology at Johns Hopkins Hospital who received 300 mg infusions of anifrolumab every 4 weeks between April and August 2024 for refractory disease. Data on demographics, disease severity, lab findings, Dermatology Life Quality Index (DLQI) and treatment details were collected. Cutaneous improvement was evaluated using the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A), while extracutaneous symptoms were assessed through lab results, physical exams and subjective reports.
resultsFour patients were identified. Clinical responses were assessed after three infusions for patients 1 and 3 and two infusions for patients 2 and 4. All patients showed improvement in cutaneous disease, with a median (range) CDASI-A reduction of 12 points or 49.4% (5-21; 26.9-77.8%). Patients 1-3 also experienced improvement in extracutaneous symptoms, including arthralgia/synovitis, dysphagia, muscle strength and creatine kinase levels. Patients 1 and 4 tapered or discontinued systemic therapies including steroid. Pre-anifrolumab DLQI data, available for two patients, showed post-treatment improvement. No anifrolumab-related adverse effects were observed.
conclusionsThis case series is the first to demonstrate anifrolumab's potential to treat refractory extracutaneous manifestations of adult-onset DM, facilitate prednisone tapering and discontinue systemic therapies. These findings provide new evidence that systemic blockade of type I interferon can manage treatment-resistant multi-organ DM manifestations, including skin, joint and muscle involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.